

Date: 10th November, 2021

To,
The Manager,
Listing Department
National Stock Exchange of India Ltd.
'Exchange Plaza'
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir / Madam,

Subject: USFDA inspection at Alembic Pharmaceuticals Injectable Facility (F-3) at Karkhadi

We would like to inform that the United States Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals' Injectable Facility (F-3) located at Karkhadi from 28th October, 2021 to 10th November, 2021. The USFDA issued a Form 483 with 10 observations.

None of the observations are related to data integrity and management believes that they are addressable.


The Company is preparing the response to the observations, which will be submitted to the USFDA.

The Company is committed to maintain the highest quality standards and compliance at all times.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited


Charandeep Singh Saluja
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123